MedTrace Logo

Standardization of a Platform of Preclinical Models Derived From NSCLC Patients

NCT07629375 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2026-06-05

No results posted yet for this study

Summary

Characterize and trace innovative nutraceuticals based on microencapsulated resveratrol and Cynara cardunculus extract, using preclinical models such as organotypic tissue slices and tumoroids created from tumor fragments derived from patients with non-small cell lung cancer. This will enable the development of combination therapies to increase the efficacy of immunotherapy in NSCLC and reduce side effects that lead to treatment discontinuation.

The market implementation of these products may offer unique advantages, including increased clinical efficacy, improved tolerability of immune checkpoint inhibitors, reduced healthcare costs, improved quality of life for patients and their families, traceability of naturally derived products, and environmental sustainability.

Conditions

Sponsors & Collaborators

  • University of Catanzaro

    collaborator OTHER

  • Regina Elena Cancer Institute

    lead OTHER

Principal Investigators

  • Paola Nisticò, Medical Doctor · IRCCS "Regina Elena" National Cancer Institude

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-24
Primary Completion
2026-04-24
Completion
2026-07-24

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07629375 on ClinicalTrials.gov